Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
North Shore Long Island Jewish Health System University of North Carolina The Cleveland Clinic |
---|---|
Information provided by: | North Shore Long Island Jewish Health System |
ClinicalTrials.gov Identifier: | NCT00814255 |
This project will test whether rosiglitazone and/or adalimumab can safely reduce proteinuria (abnormal amounts of protein in the urine) and protect kidney function better than standard treatment for patients with focal segmental glomerulosclerosis (FSGS).
Condition | Intervention | Phase |
---|---|---|
Focal Segmental Glomerulosclerosis |
Drug: Adalimumab Drug: Rosiglitazone Drug: Lisinopril, losartan, and atorvastatin |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
Official Title: | Novel Therapies for Resistant FSGS |
Estimated Enrollment: | 126 |
Study Start Date: | December 2008 |
Estimated Study Completion Date: | April 2011 |
Estimated Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
2: Experimental
Conservative medical therapy plus adalimumab
|
Drug: Adalimumab
Adalimumab 24 mg/m2 (maximum dose 40 mg) sc q 14 days
|
3: Experimental
Conservative medical therapy plus rosiglitazone
|
Drug: Rosiglitazone
4 mg/m2/day divided BID
|
1: Active Comparator
Conservative medical therapy (lisinopril, losartan, atorvastatin)
|
Drug: Lisinopril, losartan, and atorvastatin
Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
|
Ages Eligible for Study: | 1 Year to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Howard Trachtman, MD | 718-470-3423 | trachtma@lij.edu |
Contact: Debbie Gipson, MD | 919-966-2561 ext 235 | debbie_gipson@unc.med.edu |
United States, Florida | |
University of Miami | Recruiting |
Miami, Florida, United States | |
Contact: Ana Paredes, MD ana.paredes@mch.edu | |
Principal Investigator: Ana Paredes, MD | |
United States, Massachusetts | |
Boston Children's Hospital | Recruiting |
Boston, Massachusetts, United States, USA | |
Contact: Michael Somers, MD 617-355-6129 michael.somers@childrens.harvard.edu | |
Principal Investigator: Michael Somers, MD | |
United States, New York | |
Schneider Children's Hospital | Recruiting |
New Hyde Park, New York, United States, 11040 | |
Principal Investigator: Howard Trachtman, MD | |
United States, North Carolina | |
University of North Carolina | Recruiting |
Chapel Hill, North Carolina, United States, 27599-7155 | |
Contact: Debbie Gipson, MD 919-966-2561 ext 235 debbie_gipson@unc.med.edu | |
Principal Investigator: Debbie Gipson, MD |
Principal Investigator: | Howard Trachtman, MD | Schneider Children's Hospital of NS-LIJ Health System |
Principal Investigator: | Debbie Gipson, MD | University of North Carolina |
Principal Investigator: | Jennifer Gassman, PhD | The Cleveland Clinic |
Responsible Party: | Schneider Children's Hospital of NS-LIJ Health System ( Howard Trachtman MD ) |
Study ID Numbers: | DK70341FII, R33DK70341 |
Study First Received: | December 22, 2008 |
Last Updated: | December 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00814255 |
Health Authority: | United States: Food and Drug Administration; United States: Federal Government |
Primary FSGS Steroid Resistant Rosiglitazone Adalimumab Resistant primary FSGS defined as failure to achieve remission in response to corticosteroids and one other immunosuppressive medication |
Glomerulosclerosis, Focal Segmental Losartan Glomerulonephritis Urologic Diseases Nephritis Lisinopril |
Kidney Diseases Angiotensin II Adalimumab Rosiglitazone Atorvastatin Focal segmental glomerulosclerosis |
Anti-Inflammatory Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Cardiotonic Agents Antilipemic Agents Physiological Effects of Drugs Enzyme Inhibitors Cardiovascular Agents Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors |
Antihypertensive Agents Protective Agents Pharmacologic Actions Protease Inhibitors Angiotensin II Type 1 Receptor Blockers Hypoglycemic Agents Therapeutic Uses Angiotensin-Converting Enzyme Inhibitors Anti-Arrhythmia Agents Antirheumatic Agents |